Boundless Bio, Inc.
3 clinical trials · Sponsor
| Record | Firm | Date |
|---|---|---|
| Study of the Kinesin Oral Molecular Degrader BBI-940 in Subjects With Advanced or Metastatic Breast Cancer (NCT07408089) | Boundless Bio, Inc. | 2026-02-25 |
| Study of the RNR Inhibitor BBI-825 in Subjects With Tumors With Resistance Gene Amplifications (NCT06299761) | Boundless Bio, Inc. | 2024-03-28 |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications (NCT05827614) | Boundless Bio, Inc. | 2023-03-24 |
Track Boundless Bio, Inc. automatically
Every clearance here is in the API, with alerts when new ones post.